Back to Newsroom
Back to Newsroom

Healthtech Solutions, Inc. Completes Acquisition of 51 Percent of World Reach Holdings, LLC.

Friday, 31 March 2023 09:00 AM

HEALTHTECH SOLUTIONS INC.

Acquisition Strengthens Marketing and Nationwide Distribution Network for Healthtech Subsidiaries

Combination of Companies Will Contribute to Healthtech Solutions' Growth and Profitability and Will Increase Shareholder Value

TUCKAHOE, NY / ACCESSWIRE / March 31, 2023 / Healthtech Solutions Inc. (OTC PINK:HLTT), via its subsidiaries, researches, develops, manufacturers and commercializes a line of wound care products including DermaBind™, a dehydrated placental membrane allograft wound covering produced using patented technology and processes. The company today announced the acquisition of 51 percent of World Reach Holdings, LLC. The World Reach group of companies, based in Chicago, IL, is a healthcare-focused collection of boutique, forward-thinking and consciously progressive manufacturing and distribution ventures that provide patented, FDA-approved, CE-approved medical products, devices and technology solutions to B2B and B2C consumers in government, public and private sectors. The transaction was completed for an undisclosed amount of cash and stock.

The acquisition of World Reach Holdings and its subsidiaries, including World Reach Health, LLC, enables the Healthtech Solutions family of companies to tap into an established global sales and distribution network. World Reach Health supplies various branches and agencies associated with the U.S. Government, hospital institutions, long-term care facilities and private corporations with brick-and-mortar facilities, as well as to a number of international partners. Throughout the heightened demands of the COVID-19 pandemic, World Reach Health was a trusted "go-to," high-volume distributor of a multitude of diagnostic products and testing services.

Healthtech Solutions, Inc. wound care subsidiary researches, develops, manufactures and commercializes a line wound care products, including DermaBind™, which is a patented dehydrated placenta membrane allograft wound covering. DermaBind™ is used by patients suffering from burns, for treating post-surgery incision sites, diabetic foot ulcers and chronic wounds involving the skin. As of 2023, some of the largest outlets where wound care products are utilized include nursing homes and podiatry offices.

Immediately following the consolidation of the involved companies, the respective entities began marketing and distributing new-to-market products, which, in addition to the wound care items, includes EnduraKit™, a long-lasting, opioid free local anesthetic, to customers throughout North America. In the coming months, the company plans to commercialize 3 new products, including a wound care kit.

As part of the transaction, Healthtech Solutions now operates two laboratories in the Salt Lake City metro area, which includes The Clia Lab, LLC, a CLIA-certified laboratory permitted to examine a person through waived tests to assess health, diagnose and determine treatment. The facilities comprise approximately 16,000 square feet of combined lab and office space - both labs are ISO 13485 certified and provide healthcare providers with myriad testing and diagnostic solutions. The Clia Lab creates a bespoke program for each customer by delivering accurate, reliable and timely patient test results.

"By combining Healthtech Solutions and World Reach Health, we have taken a tremendous step toward our future. With Jelena Olmstead and Jim Pesoli joining our management team, we can now devote our efforts to building our business with both existing products and complementary products," said Manuel Iglesias, President of Healthtech Solutions. "We anticipate the companies will see an increase in revenue and profit this calendar year on a consolidated basis."

"I have spent over 20 years in the distribution of medical products and services, and never before have I seen so many potential opportunities that, with proper marketing and distribution, could add substantially to the improvement of patient well-being while growing both companies," said Jelena Olmstead, CEO of Healthtech Solutions. "With the changes in testing, and healthcare in general, and the way the medical profession is addressing these changes, we expect continued growth and expansion. We strive to stay at the forefront of developing and/or acquiring rights to new-to-market products and expanding our overall scope of patient outcome-focused services; this ensures our growth will be consistent and trending upward."

About Healthtech Solutions

Healthtech Solutions Inc. (OTC: HLTT), which is currently being renamed and rebranded as World Reach Holdings, Inc., is an innovative portfolio-model life sciences company focused on building solutions for patients and the healthcare system through our subsidiary companies ranging in stage from pre-clinical to commercial growth. At Healthtech, we are driven by innovation and people. At our core, our philosophy is highly motivated people with ambitious goals can achieve breakthroughs with the right organizational support. By identifying and building visionary teams within an ecosystem that fuels their strengths, we believe we can collectively accelerate the next wave of advancements in healthcare. From our perspective, breakthroughs often occur at the intersection of multiple approaches, so we are agnostic to the solution - therapeutics, devices, diagnostics, digital technology, or a combination. In fact, we hypothesize that some of the most promising breakthroughs will occur at the interface of these traditional silos, which has already begun to occur. Healthcare, illness, and injury are multifactorial, and we believe the solutions often need to be multi-pronged to succeed. For more information please visit www.WorldReachHoldings.com.

Safe Harbor Statement

This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements, including without limitation, management's examination of historical operating trends and data, as well as estimates of future sales, operating margin, cash flow, effective tax rate or other future operating performance or financial results, are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Because these forward- looking statements involve risks and uncertainties, the outcome could differ materially from those set out in the forward- looking statements for a variety of reasons, including without limitation, changes in global light vehicle production; fluctuation in vehicle production schedules for which the Company is a supplier, changes in general industry and market conditions, changes in and the successful execution of our capacity alignment, restructuring and cost reduction initiatives discussed herein and the market reaction thereto; loss of business from increased competition; higher raw material, fuel and energy costs; changes in consumer and customer preferences for end products; customer losses; changes in regulatory conditions; customer bankruptcies or divestiture of customer brands; unfavorable fluctuations in currencies or interest rates among the various jurisdictions in which we operate; component shortages; market acceptance of our new products; costs or difficulties related to the integration of any new or acquired businesses and technologies; continued uncertainty in pricing negotiations with customers, our ability to be awarded new business; product liability, warranty and recall...

Investor Relations

Michael Porter, President
Porter, LeVay & Rose, Inc.
[email protected]
@PlRinvest

SOURCE: HEALTHTECH SOLUTIONS INC.

Topic:
Mergers and Acquisitions
Back to newsroom
Back to Newsroom
Share by: